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Successful treatment with intraluminal fibrinogen injection of serous
leakage from a polytetrafluoroethylene Blalock-Taussig shunt
Arata Murakami, MD, Katsuhide Maeda, MD, Hiroo Takayama, MD, Tetsuhiro Takaoka, MD, Jyotaro Kobayashi, MD, and
Shinichi Takamoto, MD, Tokyo, Japan
We report a case of excessive serous fluid leakagefrom a polytetrafluoroethylene (PTFE) Blalock-Taussig shunt (BTS) that was successfully treatedwith intraluminal fibrinogen injection.
Clinical Summary
A 1-month-old boy weighing 3 kg underwent a left modified BTS
with a 3.5-mm expanded PTFE graft to relieve cyanosis caused by
tetralogy of Fallot. Three days later, transient bleeding through the
chest drain was noted, but it spontaneously stopped, resulting in
the formation of a left upper mediastinal mass. Three weeks later,
growth of the mass was noticed on a chest radiograph, and ultra-
sonography revealed a heterogeneous mass with perigraft fluid
collection. The size of the mass increased daily despite infusion of
packs of frozen plasma (plasma fibrinogen level, 71 mg/dL), and it
eventually filled the upper half of the left thoracic cavity. Emer-
gency thoracotomy was performed on the 29th postoperative day.
Reoperation revealed a gelatinous seroma (6  8 cm) envel-
oping the graft. The seroma contained serous fluid around the
graft. Constant serous leakage from the semitranslucent colored
graft was observed (Figure 1, A) at a rate of 4 g in 5 minutes.
Intravenous administration of fibrinogen proved ineffective.
A vascular clamp was placed at each end of the graft. The blood
in the lumen of the graft was aspirated out, and 1.0 mL of
fibrinogen-rich solution (solution A, Bolheal, 1.0 mL of which
contains 80 mg of human fibrinogen, 75 U of human plasma-
derived blood clotting factor XIII, and 1000 KIE of bovine apro-
tinin; Chemo-Sero Therapeutic Research Institute, Kumamoto,
Japan) was injected through a 22-gauge needle under low pressure
for 5 minutes until the solution could be seen extruding through the
graft. The injection was repeated again, and the residual solution
was removed by means of irrigation through a small incision in the
graft. The incision was closed with 7-0 polypropylene sutures. The
clamps were gently released on the pulmonary artery side first and
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Figure 1. A, A gelatinous seroma enveloping the weeping graft. B, Serous leakage was instantaneously stopped
with intraluminal fibrinogen injection.
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then the subclavian artery side. The serous leakage immediately
stopped (Figure 1, B). Postoperatively, fibrinogen (heated and
freeze-dried human fibrinogen; Fibrinogen HT; Yoshitomi, Inc,
Osaka, Japan) was administered to maintain the serum fibrinogen
level at greater than 150 mg/dL, and tranexamic acid
(Transamin-G; Dai-ichi, Inc, Tokyo, Japan) was administered as
antifibrinolytic therapy. The patient was discharged on the 10th
postoperative day. The graft was proved to be patent at the
2-month follow up.
Discussion
Excess serous fluid leakage from PTFE-modified BTSs is encoun-
tered after approximately 20% of operations,1,2 but the mechanism
has not been clearly identified. Maitland and coworkers3 reported
successful treatment of 2 cases of massive serous leakage by
means of intraluminal injection of fibrin glue. Suzuki and associ-
ates4 reported the effectiveness of grafts pretreated with fibrinogen
in preventing serous leakage and a good long-term patency rate of
the pretreated grafts. We injected fibrinogen alone intraluminally
to eliminate the risk of graft occlusion in a case of serous leakage
and a giant seroma. Our case demonstrated that extrusion of
fibrinogen through the graft has an excellent sealing effect. We
speculated that the fibrinogen formed fibrin clots in the PTFE graft
wall by contacting thrombin and calcium hydrochloride in the
patient’s own blood. We recommend this method when symptom-
atic serous leakage is resistant to intravenous fibrinogen adminis-
tration.5
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